Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up

Medicine and Dentistry

• Patient 100%
• Enzyme Replacement Therapy 72%
• Glycogen Storage Disease Type II 72%
• Lung Function 36%
• Muscle Function 27%
• Diseases 18%
• Adverse Event 18%
• Early Diagnosis 18%
• Enzyme 9%
• Follow up 9%
• Deterioration 9%
• Disease Course 9%
• Autosomal Recessive Disorder 9%
• Motor Performance 9%
• Anaphylaxis 9%
• Evaluation Study 9%
• Glucan 1,4 Alpha Glucosidase 9%
• Alpha Glucosidase 9%
• Laboratory 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Glycogen Storage Disease Type 2 72%
• Clinical Study 27%
• Diseases 18%
• Adverse Event 18%
• Enzyme 9%
• Glucan 1,4 Alpha Glucosidase 9%
• Alpha Glucosidase 9%
• Prognosis 9%
• Anaphylaxis 9%
• Deterioration 9%
• Disease Course 9%

Biochemistry, Genetics and Molecular Biology

• Lysozyme 81%
• Lung Function 36%
• Muscle Function 27%
• Acid Alpha-Glucosidase 9%
• Alpha-Glucosidase 9%